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Unraveling the molecular clues of liver proliferation has become conceivable thanks to the model of two-third hepatectomy.
The synchronicity and the well-scheduled aspect of this process allow scientists to slowly decipher this mystery. During this
phenomenon, quiescent hepatocytes of the remnant lobes are able to reenter into the cell cycle initiating the G1-S progression
synchronously before completing the cell cycle. The major role played by this step of the cell cycle has been emphasized by loss-
of-function studies showing a delay or a lack of coordination in the hepatocytes G1-S progression. Two growth factor receptors,
c-Met and EGFR, tightly drive this transition. Due to the level of complexity surrounding EGFR signaling, involving numerous
ligands, highly controlled regulations and multiple downstream pathways, we chose to focus on the EGFR pathway for this paper.
We will ﬁrst describe the EGFR pathway in its integrity and then address its essential role in the G1/S phase transition for
hepatocyte proliferation. Recently, other levels of control have been discovered to monitor this pathway, which will lead us to
discuss regulations of the EGFR pathway and highlight the potential eﬀect of misregulations in pathologies.
1.Introduction
Althoughmammalshavealmostcompletelylostthefascinat-
ingregenerationcapacitiesofamphibians,theirliverretained
this unique ability. This process is evolutionarily conserved,
presumably because it is critical to mammals’ survival. Two-
thirds partial hepatectomy (PH) in rodents has been used
extensively to decipher the molecular and cellular clues of
liver regeneration. During this process, the liver regenerates
through hepatocytes, without the help of a stem cell com-
partment. A particularly fascinating point about this process
is that near all quiescent and diﬀerentiated hepatocytes quit
the G0 phase in a tightly synchronous manner to progress
into the G1/S phase transition and replicate their DNA. This
massive coordinated entry into the cell cycle is illustrated by
a sharp peak of BrdU (Bromodeoxyuridine) incorporation
whose timing diﬀers among species (24 hours in rats and
36 to 42 hours in mice), reﬂecting the variability in the
length of the G1 phase. Even if hepatocyte S phase entry
is tightly synchronized, hepatocyte replication starts from
periportal area and progresses rapidly towards perivenous
area.Othernonparenchymalcellssuchasstellatecells,biliary
and endothelial cells proliferate after hepatocytes, respond-
ing potentially to other signals.
This paper will focus on the molecular mechanisms
involved in this synchronous entry into the cell cycle,
highlighting the speciﬁc role of the epidermal growth factor
receptor (EGFR) during this process in all its complexity.
2.GrowthFactorsandtheSynchronousEntryof
theHepatocytesintotheCellCycle
Hepatocyte proliferation is preceded by an inﬂammatory
stimulus, described in the pioneering work of Nelson Fausto
as the “priming phase” [1, 2]. This ﬁrst step is reversible
since, without the subsequent involvement of growth factors,
hepatocytes do not progress through cell cycle and return
to quiescence. It involves the secretion of cytokines by2 International Journal of Hepatology
nonparenchymal cells such as Kupﬀer cells and poises hep-
atocytes to become receptive to these growth factors [3, 4].
In vivo, this priming stage is required since hepatocytes
exhibit only a minimal response to transforming growth
factor alpha (TGF-α), epidermal growth factor (EGF), or
hepatocyte growth factor (HGF) without it. In contrast,
these factors are potent mitogens in vitro [5–8]. In primary
culture, hepatocytes replicate their DNA synchronously after
addition of EGFR ligands, suggesting that isolation of
hepatocytes from the liver induces priming [6, 9, 10]a n df o r
review [11–13].
After cytokines have triggered the G0 to G1 phase tran-
sition, required growth factors for the progression through
the cell cycle into the S phase are signaling through two main
tyrosine-kinase receptors: EGFR and c-Met.
HGF is the main ligand of c-Met receptor. It is mainly
secreted by macrophages and endothelial liver cells [14].
Overexpression of HGF in the liver of transgenic mice
increases hepatocyte proliferation during postnatal develop-
ment and accelerated liver regeneration after PH but has
minor eﬀects at adult stage in a quiescent liver [15–17]. On
the contrary, conditional deletion of this receptor, as well
as studies using RNAi in the liver of mice, caused either a
signiﬁcant decrease in the peak of proliferation [18, 19]o r
ad e l a yo fS - p h a s ee n t ry[ 20]. Moreover, Thorgeirsson’s team
indicatedthatc-MetisrequiredforG2/Mprogressionaswell
as entering the cell cycle in vivo [19].
As opposed to HGF/c-Met axis, EGFR has numerous
ligands (EGF, amphiregulin, HB-EGF, TGF-α, epiregulin,
betacellulin, epigen). For this reason, the implication of this
pathway after PH has been studied extensively through-
out the years, as it involves several growth factors and
downstream pathways to control the proliferation balance.
Interestingly,Mitchelletal.showedthatafter1/3PHinmice,
there is a lack of a synchronous wave of DNA replication
[21]. They then observed that, among the growth factors
induced during liver regeneration, the secretion peak of
HB-EGF usually observed 24h after 2/3 PH was absent
after the 1/3 PH [21]. HB-EGF injection in 1/3 hepatec-
tomized mice is then suﬃcient to restore a peak of BrdU
incorporation in hepatocytes [21]. Besides highlighting the
robustmitogenpotentialofHB-EGF,thisstudyindicatedthe
importance of the EGFR pathway in the synchronous induc-
tion of DNA replication in a dose-dependent manner after
PH.
3.EGFRPathway
3.1. General Description of EGFR. The Epidermal Growth
Factor Receptor (EGFR), also known as ErbB-1, is a plasma
membrane glycoprotein, which belongs to the ErbB family
of receptor tyrosine kinases (RTKs) jointly with ErbB-2,
ErbB-3, and ErbB-4 [22]. It contains an extracellular domain
with two cysteine-rich regions, a single transmembrane-
spanning region, and a well-conserved cytoplasmic tyrosine
kinase domain [23]. Upon ligand binding, ErbB proteins can
either homo- or heterodimerize with other members of the
ErbB family to activate downstream signaling pathways that
regulate proliferation, growth, and diﬀerentiation [24].
EGFR was the ﬁrst member of this family as well as the
ﬁrst RTK to be discovered [25] and plays an essential role
in the development of epithelial cells but also in tumors
of epithelial cell origin [26]. Ligand induced EGFR dimer-
ization leads to receptor autophosphorylation at tyrosine
residues (Figure 1). Some of them can be regulated via other
s i g n a l sl i k eg r o w t hh o r m o n e[ 27, 28] or oxidative stress
[29, 30]. Phosphotyrosine residues allow the recruitment
of speciﬁc partners to activate diﬀerent downstream path-
ways. EGFR controls a variety of signals ranging from cell
proliferation, cell motility, apoptosis decrease, to epithelial-
mesenchymal transition, upregulation of matrix metallopro-
teinases, and has even been proposed to be involved in stem-
cell maintenance [31]. Moreover, EGFR has also been shown
to regulate downstream targets by directly translocating its
internal region into the nucleus, activating cell cycle genes
such as Cyclin D1 [32] or genes involved in inﬂammation
like COX-2 [33]. Interestingly, Cox-2-deﬁcient mice showed
an impaired liver regeneration [34].
EGFR signaling is regulated in part by endocytic sorting
[35,36].Uponligandbinding,EGFRisinternalizedandtraf-
ﬁcked to the endosome. Depending on ligand/EGFR com-
plex stability [37] and ubiquitination process by cbl family
proteins [38], EGFR is either degraded in the lysosomal
compartment or recycled to the plasma membrane [35,
37, 39]. This process may represent an important negative
feedback regulatory mechanism to control EGFR signaling
[35, 36].
3.2. EGFR Pathway in the Liver. There is a strong expression
of EGFR in the adult liver, but also during development and
regeneration, suggesting an important role for its function
[40]. Disruption of EGFR in mice has led to death from
mid-gestation up to third week depending on the genetic
background, showing various signs of abnormalities to mul-
tipleorgansincludingtheskin,kidney,brain,gastrointestinal
tract,andtheliverwiththickenedhepatocytecords,distorted
sinusoidal anatomy, and abnormally vacuolized nuclei [41].
Speciﬁc deletion of EGFR in hepatocytes did not reveal any
phenotypical abnormality apart from a reduction in body
weight [42]. It has been shown that EGFR ligands exhibit
functional diﬀerences in models of paracrine and autocrine
signaling [43]. Several ligands, such as amphiregulin, epi-
dermal growth factor (EGF), heparin-binding EGF (HB-
EGF), betacellulin, epiregulin, and TGF-α have been shown
to be able to activate the EGFR pathway and some of them
induced strong mitogens signals in the liver [44]. There is
no evidence that these ligands bind speciﬁcally to EGFR and
not to other ErbB proteins with whom EGFR can dimerize,
although their essential role during liver regeneration has
been demonstrated for some of them as described below
[45].
There are four main downstream pathways usually asso-
ciated with EGFR activation: Ras/MAPK, PI3K/Akt, signal
transducer and activator of transcription (Stats) and phos-
pholipase C-gamma 1 (PLCΥ1) pathways [46]( Figure 1).
However, it has been shown in diﬀerent epithelial cell types
in vitro that ligands binding to EGFR induce diﬀerentInternational Journal of Hepatology 3
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Figure 1: EGFR induced signaling pathways. The major source of each EGFR ligands involved in liver regeneration is schematized.
Amphiregulin liver induction right after PH is not suﬃcient to determine the cellular origin of this secretion. Upon binding of its ligands,
EGFR homodimerizes leading to phosphorylation of many tyrosine residues localized in the carboxy-terminal tail of EGFR. Phospho-EGFR
is then able to recruit adaptor proteins. They transduce the EGFR signaling by inducing several EGFR-dependent pathways, including the
RAS-MAPkinase, PI3K-AKT, PLCγ, and Stat pathways. Collectively these pathways control proliferation, diﬀerentiation, migration, and
survival of the cell.
downstream signaling pathways according to their aﬃnity.
While high aﬃnity ligands (10% of EGFR pool) activate
Ras/MAPK and PI3K/Akt pathways, low aﬃnity ligands
(90% of EGFR pool) induce Stats and PLCΥ1p a t h w a y s
[47]. It is now clear that those diﬀerent pathways are highly
interlinked, but for the following they will be described
separately.
Once activated, the internal region of EGFR can serve as
a docking site for Src homology 2 domains such as Grb2 and
Shc [48, 49]. Grb2 or Shc then interacts with Ras, leading
to an interaction with Raf, which will in terms activate
the whole MAP kinases pathway [48–50]. The activation
of EGFR can also provide a docking site for p85, which is
the protein subunit of PI3K. Once activated, it will in turn
phosphorylate Akt to promote cell survival and proliferation
[51]. In the liver, EGFR-dependent Stats activation does not
depend upon JAK kinases activation, as it is usually the
case. Instead, Stats have been proposed to be constitutively
associated to EGFR, becoming active directly by EGFR
phosphorylation [49, 52]. More recently, the Src-kinase has
beenproposedtoactivateStatsthroughEGFRactivation[53,
54]. The precise mechanism of PLCΥ1 activation remains
unclear, but it appears that PLCΥ1 is also directly associated
to EGFR but does not need tyrosine phosphorylation [55].
The activation of PLCΥ1 will yield 1,2-diacylglycerol (DAG)
and inositol 1,4,5-triphosphate (IP3). DAG can then activate
PKC whereas IP3 can activate Ca2+-dependent pathways
[56].
4. EGFRPathwayduringthe G1-S
PhaseinHepatocytes
4.1. The Input of EGFR Ligands in Invalidation Mouse Models.
ThemitogenicactionoftheEGFRsignalwasﬁrstdetermined
in vitro, on primary culture of hepatocytes. EGFR ligands
were added in serum-free medium culture and tested for
their capacity to induce hepatocyte proliferation in rodents.
Four of them: TGF-α, HB-EGF, EGF, amphiregulin, were
determined as hepatocyte growth factors since they allow
their synchronized S phase entry [5–8].
After 2/3 PH, the protein level of these EGFR ligands
increasesrapidly[8,57,58].Theirmitogenicrolewasstudied
in vivo using ligand injection, gene overexpression, RNA
interference, and conditional gene knockout strategies.
Loss of HB-EGF expression by knocking-out the gene
led to major impairment of liver regeneration character-
ized by the absence of hepatocytes synchronized S phase
entry [21]. Conversely, liver HB-EGF overexpression in
transgenic mice induced a drastic increase of proliferating
hepatocytes compared to wildtype nontransgenic littermates
[59].
Salivary glands ablation in rodent [60–62], which are
the main source of EGF, provoke a main liver regenerative
defect hepatocytes being blocked in G1 phase, as it is the case
in the conditional amphiregulin knockout mice [8]. After
salivary glands ablation, EGF injections restore hepatocyte
proliferation in rats [60–62].4 International Journal of Hepatology
Thus, misregulation of these three latter EGFR ligands
leads to the same proﬁle of liver regenerative defect char-
acterized by a desynchronized S phase entry of hepatocytes.
These results then suggest that these ligands are not redun-
dant during liver regeneration. In contrast to these three
liver EGFR ligands, gene inactivation of TGF-α in mice had
no eﬀect on liver regeneration [63] although it has been
demonstrated on hepatocytes primary culture, that TGF-α
hasthesamemitogencapacitiesasEGF,amphiregulinorHB-
EGF [5, 6, 8, 64–66].
Diﬀerent non-exclusive hypotheses can be proposed
to understand the non-redundancy of HB-EGF, EGF and
amphiregulin ligands. This can be explained by the impor-
tance of ligands sequential binding, by diﬀerent ligands
activating diﬀerent EGFR downstream pathways or by the
necessity to reach a threshold of total ligands quantity, in
order to induce proliferative signals. Regarding TGF-α, the
paradoxical results obtained in vitro and in vivo, can be
explained if we hypothesize that already expressed EGFR
ligands compensate for TGF-α. Genetic replacement of
one ligand by another one at the same physiological level
using knocking-in strategies, could help to understand these
discrepancies.
4.2.TheEGFReceptorduringRegeneration. TheroleofEGFR
(ErbB1) in the G1 phase of the cell cycle in hepatocytes
has also been studied in vivo either by RNA interference
injection in rats [67] or by conditional gene inactivation in
mice [42]. Both experiments induced a major impairment
of liver regeneration resulting in an altered progression into
the G1 phase. However, mutant livers can ﬁnally complete
regeneration suggesting that EGFR is a critical regulator
of hepatocyte proliferation in the initial phases of this
process. As opposed to other tissues, ErbB-2 and ErbB-4
are not expressed in the regenerating liver and thus, cannot
heterodimerize with EGFR [40]. However, in contrast with
liver regeneration, it has been observed that ErbB-2 is re-
expressed in primary culture of hepatocytes, participating
to the induction of proliferation in vitro [68, 69]. ErbB-3 is
induced after PH but its ligands are not known to participate
to hepatocyte proliferation [40].
The common molecular mechanism between all these
studies consists in a downregulation of cyclin D1 expression,
the ﬁrst cyclin that is activated during progression in G1
phase [70, 71]. However, there is very little information
on signaling pathways activated downstream of EGFR in
hepatocytes to induce their proliferation. In primary culture
of hepatocytes, Erk1/Erk2 and PI3K/AKT cascades have
been shown to be activated by EGF to induce hepatocyte
proliferation [72, 73]. However, during liver regeneration
of EGFR knock outs speciﬁcally in hepatocytes in mice,
none of these canonical downstream pathways were found
dysregulated [42], while livers of rats injected with an EGFR
RNAi showed a Stat3 misregulation [67]. Regarding knock
outs experiments, the authors only reported a defect in the
NF-κB and in p38 activation during the G1 phase [42].
The essential role of NF-κB during liver regeneration is to
“prime” hepatocytes and not to participate to the G1 phase
progression [4, 10]. However it was suggested that it could
control cyclin D1 transcription [74, 75]. In vitro studies
showed that EGFR could activate Ca2+ dependent pathways
such as RaI and NF-κB through the phosphorylation of
PLCγ.P L C γ is one of the possible downstream pathways
activated by EGFR. It has been shown that the increased
activity of nuclear PLC in regenerating rat occurs before
DNA synthesis peak after PH [76]. Moreover, Farrell’s group
pointed out the role of the EGFR/PLCγ axis in hepatocyte
proliferation in a model of chronic ethanol consumption
[77].
In rats injected with RNAi directed against EGFR, Stat3
transcription downregulation was observed by transcrip-
tomic approach [67]. This result may be relevant since
Stat3 is a target of EGFR and has the capacity to activate
proliferation through cyclin D1 in other cell types. However,
it would have been interesting to check both the protein
expression and activation level of Stat during the regen-
erating process, as this hypothesis does not match with
cell culture experiments. It was indeed demonstrated that
the Stats (Stat3 and Stat5) were not recruited for EGFR
dependent hepatocyte proliferation in vitro [78].
The discrepancy between the in vitro and in vivo
results makes it diﬃcult to fully understand which are the
intracellular targets required to induce the EGFR dependent
progression into the S phase.
5. Regulation of the EGFRPathway during
Liver Regeneration
5.1. Regulation of the Ligands. Liver regeneration eﬃciency
could indeed be controlled either by EGFR ligands induction
and/or by EGFR activation. While various factors have been
shown to regulate EGFR ligands in the quiescent liver, very
little is known during the regenerative process when these
factors are induced.
The Hippo signaling pathway, well known to be involved
in cell proliferation, could also regulate the EGFR pathway
through its pivotal eﬀector, YAP (Yes-associated protein).
Indeed,ithasbeenshownthatYAPregulatesamphiregulinat
a transcriptional level [79]. Interestingly, one study showed
that YAP protein level increases after PH, suggesting a role
in liver regeneration [80]. Loss of Hippo signaling in the
mouse liver has been shown to lead to YAP induction and
liver hyperplasia with hepatocytes progenitors proliferation
[81–83]. However, no study has been yet performed after
partial hepatectomy in YAP knockout mice to comfort this
potential role.
Diﬀerent members of the ADAM family induce the mat-
uration of EGFR ligands, by cleaving them, and thus increas-
ing their biodisponibility for EGFR binding [84]. ADAM
10 is able to cleave EGF transmembrane precursors [85].
ADAM 17, also known as tumour necrosis factor-α-(TNF-α-
)converting,enzyme, orTACE, canshedamphiregulin, TGF-
αandHB-EGFprecursors[86,87].Ithasbeensuggestedthat
ADAM17, upon TNF-α addition in hepatocyte cell culture,
transactivates EGFR by cleaving TGF-α, increasing hepa-
tocyte proliferation [88]. As for liver regeneration, ADAM
17 expression increases at the late G1-phase corroboratingInternational Journal of Hepatology 5
a potential regulator role of EGFR signaling during this
regenerative process [89].
5.2. Regulation of the Receptor. Regarding the receptor, we
recently pointed out the major role played by the growth
hormone(GH)pathwaytocontrolEGFR.GHisapleiotropic
hormone that plays a major role in proliferation, diﬀerentia-
tion,andmetabolismviaitsspeciﬁcreceptor.Ithasbeenpre-
viously suggested that GH signaling pathways are required
for normal liver regeneration [90, 91]. Consequently, we
recently investigated the mechanism by which GH controls
liver regeneration. GH receptor knockout mice (GHrKO)
showed a major liver regeneration impairment correlated
with a downregulation of ERK1/ERK2 activation [92]. We
showed that GH controlled the EGFR expression at the
mRNA level in liver from quiescent stage until the mid G1-
phase [92]. Most of GH physiological eﬀects are mediated by
the Stat5 transcription factor. Interestingly, EGFR expression
was drastically down regulated in the liver of mice deleted
for Stat5b in their hepatocytes [93]. However, chromatin
immunoprecipitationexperimentsfailedtodemonstratethat
Stat5b binds to EGFR promoter and suggested that it acts
indirectly through intermediate proteins [93]. IGF-1, the
major target gene of GH/Stat5b axis in the liver could have
been an interesting target since it is known to be involved in
liver regeneration control and it is drastically downregulated
in GHrKO mice [91, 94]. However, we demonstrated that it
is not the case, its forced expression in GHrKO mice hep-
atocytes failing to rescue EGFR expression (personal data).
Interestingly, GH has also been described to control EGFR
at posttranscriptional level, inducing its phosphorylation in
quiescent liver [27, 28]. Accordingly with these data, EGFR
failed to be activated by phosphorylation throughout the G1
phase in the hepatectomized GHrKO mice, even when it was
reexpressed in mid/late G1-phase [92].
Bile acids that have been shown to contribute to liver
regeneration have recently been considered as an interme-
diate in the interplay between EGFR and the Fas apoptotic
pathway. Indeed, CD95L and hydrophobic bile acids are
knowntotransactivateEGFR,butdependingonthecelltype,
CD95-EGFR-mediated signalling ends up in cell apoptosis
or cell proliferation. Thus, EGFR activation by CD95L or
bile acids can lead to hepatic stellate cell proliferation but
hepatocyte apoptosis [95].
Finally, the Wnt/β-Catenin pathway that is activated
during the mid G1-phase during liver regeneration process
could also participate to EGFR regulation during the liver
regeneration process [96, 97]. β-catenin has been proposed
to control EGFR in quiescent liver at a transcriptional level
[98], but there is no clear evidence for a direct action
of β-catenin via the putative Lef/Tcf site present on the
EGFR promoter [98]. However, liver regeneration studies
on mice deleted for ctnnb1 (the gene coding for β-catenin),
although leading to a liver regeneration delay, did not point
out an EGFR expression impairment [96, 97, 99]. We can
hypothesize that β-catenin pathway compensates for EGFR
defect in GHrKO mice from mid G1-phase when EGFR
expression was reinduced.
6. Conclusion
Altogether, these data highlight the major role played by
growth factors via EGFR in the liver regeneration process.
Its activation during the G1 phase controls the cell cycle
progression of hepatocytes from the G1 phase until the
S phase leading to the synchronized hepatocytes S-phase
entry. In liver regeneration, even though ligands have been
identiﬁed, downstream pathways leading to hepatocytes S
phase entry as well as the mechanisms that regulate EGFR
pathway activation remain to be determined. In this context,
our results point out the major role played by GH to control
its expression and activation during the regenerative process
[92].
The degree of complexity of hepatocyte proliferation’s
regulation by growth factors is reinforced by the question
of a potential crosstalk and/or redundancy between EGFR
and HGF pathways since they both induce hepatocytes
G1/S progression and can activate the same downstream
gene cascades [18–20, 42, 67]. A relationship between these
pathways has been suggested by the observation that loss
of c-Met or EGFR both lead to major liver regeneration
impairment. This could result from the necessity of two
independent pathways or by the existence of an essential
interrelation between both pathways, to induce a robust
hepatocyte proliferation signal. Since in vitro studies led to
discordant results, it should be interesting in the future to
test the redundancy or independence of c-met and EGFR
pathways for liver regeneration in double knockout mice.
Given the importance of EGFR signaling to control
hepatocytes division and its regulation by GH, it will be
interesting to determine the incidence of misregulations of
the GH/EGFR axis on the liver proliferative capacity in
hepatic physiopathology. There have been numerous studies
in human and in mice reporting defects of the GH signaling
in various liver pathologies. For example, liver cirrhosis
has been associated with the inhibition of GH signaling in
the liver [100, 101]. Obesity, often associated with hepatic
steatosis and insulinoresistance, is also characterized by a
decrease of GH level in the serum of patients [102, 103].
We found in diﬀerent mouse models that hepatic steatosis
is associated both with a downregulation of GH pathway
and a downregulation of EGFR expression (personal data).
We therefore hypothesize that the loss of liver proliferation
capacity in liver steatosis is related to the GH/EGFR axis
misregulation.
In contrast, the EGFR signaling upregulation has been
involved in cancer development in many tissues [104]. In
hepatocellular carcinoma, its misregulation was found in 60
to80percentofpatients,dependingonstudies,leadingtothe
suggestion that EGFR signaling upregulation was associated
with the increased proliferative capacity of liver tumoral cells
[105].
The complete deciphering of EGFR signaling regulatory
pathways resulting in this tricky balance will therefore be
crucial in the future to develop appropriate therapeutic
strategies allowing stimulation of hepatocyte proliferation in
chronic liver diseases if required or in contrast, to reduce it
in cases of tumoral progression.6 International Journal of Hepatology
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